Compare BridgeBio Pharma Inc (BBIO) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Nuwellis Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Nuwellis Inc trades at $1.49 (market cap $522.76K). The key difference: BridgeBio Pharma Inc is far larger — about 31773.7× Nuwellis Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | NUWE | |
|---|---|---|
Market Cap | $16.61B | $522.76K |
Sector | Health | Technology |
52-Week High | $90.17 | $220.50 |
52-Week Low | $47.29 | $1.42 |
Enterprise Value | $18.16B | -$1.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
